The FDA approved Orladeyo (berotralstat), developed by BioCryst Pharmaceuticals Inc. (BCRX), on December 3, 2020, to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.Hereditary angioedema is a rare disease characterized by recurrent attacks of severe swelling in body parts including the limbs, face, intestinal tract, and airway.Orladeyo is the first orally administered non-steroidal option for preventing HAE attacks.BioCryst has priced the drug at $485,000 per patient per year.Takeda’s Takhzyro, Shire's (a unit of Takeda), Cinryze and CSL Behring’s Haegarda are injectable drugs approved for preventing HAE attacks.Orladeyo is under review in Europe with a decision expected in March.